Philips Healthcare has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Spectral Diagnostic Suite (SpDS), a software suite of advanced visualization and analysis tools available for its IQon spectral CT scanner.
Designed to enhance spectral viewing and improve the capabilities of clinical applications, SpDS comprises three software applications: spectral-enhanced Comprehensive Cardiac Analysis (sCCA), spectral-enhanced Advanced Vessel Analysis (sAVA), and spectral-enhanced Tumor Tracking (sTT), according to the vendor. SpDS offers spectral capabilities within traditional CT applications, allowing clinicians to utilize spectral information as they need to without having to switch to special modes or other workstations, Philips said.
Physicians can also use on-demand spectral analysis of a particular region to further analyze incidental findings, which reduces radiation dose exposure by avoiding the need to recall patients for additional imaging, the vendor said. The suite supports viewing analysis of spectral datasets in settings such as reading rooms, PACS workstations, and remote locations.
